Sugi Predict

Sugi Predict / Targets / AGPS

AGPS

Alkyldihydroxyacetonephosphate synthase, peroxisomal · O00116 · AGPS on Sugi Atlas →

440 patent compounds predicted against AGPS, 383 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL4699731 SCHEMBL4699731 1.00 2/20
SCHEMBL16111548 SCHEMBL16111548 1.00 2/20
SCHEMBL29358745 SCHEMBL29358745 1.00 2/20
SCHEMBL29380618 SCHEMBL29380618 1.00 2/20
SCHEMBL29931136 SCHEMBL29931136 1.00 2/20
SCHEMBL4697866 SCHEMBL4697866 0.89 2/20
SCHEMBL24532075 SCHEMBL24532075 0.89 2/20
SCHEMBL4697696 SCHEMBL4697696 0.86 2/20
SCHEMBL23092285 SCHEMBL23092285 0.86 2/20
SCHEMBL29688472 SCHEMBL29688472 0.86 2/20
SCHEMBL22024695 SCHEMBL22024695 0.86 2/20
SCHEMBL16136600 SCHEMBL16136600 0.84 2/20
SCHEMBL24532058 SCHEMBL24532058 0.83 2/20
SCHEMBL4699947 SCHEMBL4699947 0.83 2/20
SCHEMBL22025026 SCHEMBL22025026 0.82 2/20
SCHEMBL22119546 SCHEMBL22119546 0.82 2/20
SCHEMBL24532062 SCHEMBL24532062 0.82 2/20
SCHEMBL18804561 SCHEMBL18804561 0.81 2/20
SCHEMBL22024561 SCHEMBL22024561 0.81 2/20
SCHEMBL22025030 SCHEMBL22025030 0.81 2/20

Clinical trials — most relevant to AGPS by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Bezafibrate Trial in CPT2 Deficiency PHASE3UNKNOWN
Aspirin and Renal Disease Progression in Patients With Type 2 Diabetes PHASE3UNKNOWN
NEO100 and High-Grade Meningioma PHASE2RECRUITING
Safety, Tolerability, and Exploratory Efficacy of AGP100 in Patients With Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT) PHASE2RECRUITING
Acetylcarnitine and Insulin Sensitivity PHASE2COMPLETED
Safety, Tolerability and Pharmacokinetics of Benfo-Oxythiamine (B-OT) in Healthy Volunteers PHASE1COMPLETED
Effect of Gemfibrozil on Serum Glycosylphosphatidylinositol (GPI) Phospholipase D and Triglycerides PHASE1COMPLETED
Efficacy of Sunlight Activated Synthetic Porphyrin in COVID-19 Infected Patients PHASE1UNKNOWN
RCDP Natural History Study nanUNKNOWN
Identification of Acute Intermittent Porphyria Modifying Genes nanRECRUITING
Unraveling Genetics of HypoPhosPhatasia (HPP Genetics) nanCOMPLETED
Glycine and Magnesium+Thiamine for the Treatment of Primary Ciliary Dyskinesia nanRECRUITING
Observational Study of Acute Intermittent Porphyria Patients nanCOMPLETED
Gene Expression Profiles in Generalized Aggressive Periodontitis: A Gene Network-based Microarray Analysis nanCOMPLETED
Genetic Studies of Lysosomal Storage Disorders nanENROLLING_BY_INVITATION
Cardiotoxicity of Aluminum Phosphide Poisoning; Tropinin and CKmb as Early Biomarkers nanUNKNOWN
Droplet Digital PCR and PCR-free BIOSensors for the Detection of Resistance-associated SNPs in Pneumocystis Jirovecii nanACTIVE_NOT_RECRUITING
Genetic Analysis of Gray Platelet Syndrome nanCOMPLETED
Using Next-generation Sequencing in the Diagnosis of Epilepsy and/or Intellectual Disability in a Pediatric Cohorte nanCOMPLETED
Effect of Omega-3 Fatty Acids Supplementation on Hypertriglyceridemia in Pediatric Patients With Obesity. nanCOMPLETED
Health Impacts of Sustainable Ingredient Selection in the Food and Drink Industry - ALTERNATIVE PROTEIN STUDY nanCOMPLETED
Nephroprotective Effects of Carnitine and (PDE5) Inhibitor Agent Against Contrast Media-induced Nephropathy (CMN) nanUNKNOWN
Effect of Sulfur Amino Acid Depletion and Acetaminophen on Plasma Glutatione nanCOMPLETED
Effect of an Polyphenolic Beverage in Healthy Volunteers nanACTIVE_NOT_RECRUITING
Exome Sequencing for Atypical Femoral Fractures nanCOMPLETED
Presence of Cyclopropane Fatty Acids (CPFA) in Human Plasma nanCOMPLETED
Vulvodynia: Identification of Potential Relevant Biomarkers nanCOMPLETED
CADASIL Disease Discovery nanCOMPLETED
Positional Cloning of the Gene(s) Responsible for Alagille Syndrome nanCOMPLETED
Protein Synthesis in the Brain of Patients With Fragile X Syndrome nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a AGPS binder may also engage these)

ProteinNameSimilarity
Q9EQR2 — 1.000 Q9EQR2 →
P97275 — 1.000 P97275 →
Q8C0I1 — 0.999 Q8C0I1 →
Q9V778 — 0.983 Q9V778 →
O45218 — 0.983 O45218 →
Q90YK3 — 0.977 Q90YK3 →
Q94AX4 — 0.976 Q94AX4 →
A1L258 — 0.976 A1L258 →
Q7XI14 — 0.975 Q7XI14 →
B8B7X6 — 0.974 B8B7X6 →
Q58H57 — 0.974 Q58H57 →
F1QXM5 — 0.973 F1QXM5 →
Q8VCH6 — 0.973 Q8VCH6 →
CBS Cystathionine beta-synthase 0.973 landscape →
DHCR24 Delta(24)-sterol reductase 0.973 landscape →
O23240 — 0.973 O23240 →
Q60HC5 — 0.973 Q60HC5 →
Q6ESI7 — 0.972 Q6ESI7 →
A6QLJ3 — 0.972 A6QLJ3 →
Q6NUA1 — 0.971 Q6NUA1 →
Q12627 — 0.971 Q12627 →
Q5BQE6 — 0.971 Q5BQE6 →
A8E657 — 0.971 A8E657 →
NAT10 RNA cytidine acetyltransferase 0.971 landscape →
Q6UB28 — 0.971 Q6UB28 →
Q9UDR5 — 0.971 Q9UDR5 →
Q4QRK0 — 0.971 Q4QRK0 →
A9RBS1 — 0.970 A9RBS1 →
PRMT5 Protein arginine N-methyltransferase 5 0.970 landscape →
Q9CPW9 — 0.970 Q9CPW9 →